Hypertension and atrial fibrillation
- 1 February 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hypertension
- Vol. 30 (2), 239-252
- https://doi.org/10.1097/hjh.0b013e32834f03bf
Abstract
Hypertension is the most common cardiovascular disorder and atrial fibrillation is the most common clinically significant arrhythmia. Both these conditions frequently coexist and their prevalence increases rapidly with aging. There are different risk factors and clinical conditions predisposing to the development of atrial fibrillation, but due its high prevalence, hypertension is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes, neurohormonal activation, fibrosis, atherosclerosis, etc.) have been advocated to explain the onset of atrial fibrillation. The presence of atrial fibrillation per se increases the risk of stroke but its coexistence with high blood pressure leads to an abrupt increase of cardiovascular complications. Different risk models are available for the risk stratification and the prevention of thromboembolism in patients with atrial fibrillation. In all of them hypertension is present and is an important risk factor. Antihypertensive treatment may contribute to reduce this risk, and it seems some classes are superior to others in the prevention of new-onset atrial fibrillation and prevention of stroke. Antithrombotic treatment with warfarin is effective in the prevention of thromboembolic events, although quite recently, new classes of anticoagulants that do not require international normalized ratio monitoring have been introduced with promising results.This publication has 94 references indexed in Scilit:
- Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and FlutterCanadian Journal of Cardiology, 2011
- Validation of an Atrial Fibrillation Risk Algorithm in Whites and African AmericansJAMA Internal Medicine, 2010
- Birth Weight Is a Significant Risk Factor for Incident Atrial FibrillationCirculation, 2010
- Telmisartan to Prevent Recurrent Stroke and Cardiovascular EventsThe New England Journal of Medicine, 2008
- Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation studyAmerican Heart Journal, 2007
- Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trialBMJ, 2007
- RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE IIAmerican Heart Journal, 2006
- Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillationAmerican Heart Journal, 2006
- Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trialAmerican Heart Journal, 2006
- Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)American Heart Journal, 2003